These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 12769338)

  • 1. Evaluation of imipenem 1.5 g daily in febrile patients with short duration neutropenia after chemotherapy for non-leukemic hematologic malignancies and solid tumors: personal experience and review of the literature.
    Jourdan E; Defez C; Topart D; Richard B; Bellabas H; Fabbro-Peray P; Jourdan J; Sotto A
    Leuk Lymphoma; 2003 Apr; 44(4):619-26. PubMed ID: 12769338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies.
    Cherif H; Björkholm M; Engervall P; Johansson P; Ljungman P; Hast R; Kalin M
    Scand J Infect Dis; 2004; 36(8):593-600. PubMed ID: 15370671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer).
    Biron P; Fuhrmann C; Cure H; Viens P; Lefebvre D; Thyss A; Viot M; Soler-Michel P; Rollin C; Grès JJ
    J Antimicrob Chemother; 1998 Oct; 42(4):511-8. PubMed ID: 9818751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imipenem-cilastatin versus piperacillin-tazobactam as monotherapy in febrile neutropenia.
    Vural S; Erdem E; Gulec SG; Yildirmak Y; Kebudi R
    Pediatr Int; 2010 Apr; 52(2):262-7. PubMed ID: 19744230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imipenem/cilastatin with or without glycopeptide as initial antibiotic therapy for recipients of autologous stem cell transplantation: results of a Spanish multicenter study.
    de la Rubia J; Montesinos P; Martino R; Jarque I; Rovira M; Vázquez L; López J; Batlle M; de la Cámara R; Juliá A; Lahuerta JJ; Debén G; Díaz J; García R; Sanz MA
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):512-6. PubMed ID: 19285640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Imipenem combined with teicoplanin or vancomycin in the initial empirical treatment of febrile neutropenia. Analysis of the primary response and of a global sequential strategy in 126 episodes].
    Figuera A; Tomás JF; Hernández L; Jiménez ML; Peñarrubia MJ; del Rey MC; Arranz R; Cámara R; López-Lorenzo JL; Fernández-Rañada JM
    Rev Clin Esp; 1996 Aug; 196(8):515-22. PubMed ID: 8984537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imipenem in the treatment of febrile neutropenic children.
    Erbey F; Bayram I; Yilma S; Tanyeli A
    Asian Pac J Cancer Prev; 2009; 10(5):921-4. PubMed ID: 20104991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary Infections in Febrile Neutropenia in Hematological Malignancies: More Than Another Febrile Neutropenic Episode.
    Demirel A; Tabak F; Ar MC; Mete B; Öngören Ş; Yemişen M; Özaras R; Eşkazan E; Başlar Z; Mert A; Soysal T; Ferhanoğlu B; Aydın Y; Öztürk R
    Turk J Haematol; 2015 Sep; 32(3):243-50. PubMed ID: 25913035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Piperacillin-tazobactam vs. imipenem-cilastatin as empirical therapy in hematopoietic stem cell transplantation recipients with febrile neutropenia.
    Jing Y; Li J; Yuan L; Zhao X; Wang Q; Yu L; Zhou D; Huang W
    Clin Transplant; 2016 Mar; 30(3):263-9. PubMed ID: 26701371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective, randomized, double-blinded, placebo-controlled trial of empirical teicoplanin in febrile neutropenia with persistent fever after imipenem monotherapy.
    Erjavec Z; de Vries-Hospers HG; Laseur M; Halie RM; Daenen S
    J Antimicrob Chemother; 2000 Jun; 45(6):843-9. PubMed ID: 10837439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial comparing netilmicin plus imipenem-cilastatin versus netilmicin plus ceftazidime as empiric therapy for febrile neutropenic bone marrow transplant recipients.
    Laszlo D; Bacci S; Bosi A; Fanci R; Guidi S; Saccardi R; Vannucchi AM; Rossi Ferrini P
    J Chemother; 1997 Apr; 9(2):95-101. PubMed ID: 9176746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study.
    Sanz MA; Bermúdez A; Rovira M; Besalduch J; Pascual MJ; Nocea G; Sanz-Rodríguez C;
    Curr Med Res Opin; 2005 May; 21(5):645-55. PubMed ID: 15969864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infections of febrile neutropenic patients in malignant hematological diseases.
    Rókusz L; Liptay L
    Mil Med; 2003 May; 168(5):355-9. PubMed ID: 12775168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imipenem-cilastatin for empirical therapy in neutropenic patients with fever: an open study in patients with hematologic malignancies.
    Huijgens PC; Ossenkoppele GJ; Weijers TF; van Loenen AC; Simoons-Smit AM; Wijermans PW; van Pampus EC; Langenhuijsen MM
    Eur J Haematol; 1991 Jan; 46(1):42-6. PubMed ID: 1988306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three-day treatment with imipenem for unexplained fever during prolonged neutropaenia in haematology patients receiving fluoroquinolone and fluconazole prophylaxis: a prospective observational safety study.
    Slobbe L; Waal Lv; Jongman LR; Lugtenburg PJ; Rijnders BJ
    Eur J Cancer; 2009 Nov; 45(16):2810-7. PubMed ID: 19647995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early discontinuation of empirical antibacterial therapy in febrile neutropenia: the ANTIBIOSTOP study.
    Le Clech L; Talarmin JP; Couturier MA; Ianotto JC; Nicol C; Le Calloch R; Dos Santos S; Hutin P; Tandé D; Cogulet V; Berthou C; Guillerm G
    Infect Dis (Lond); 2018 Jul; 50(7):539-549. PubMed ID: 29451055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children.
    Aksoylar S; Cetingül N; Kantar M; Karapinar D; Kavakli K; Kansoy S
    Pediatr Hematol Oncol; 2004 Mar; 21(2):115-23. PubMed ID: 15160510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of an alternative meropenem dosing strategy compared with imipenem-cilastatin or traditional meropenem dosing after cefepime failure or intolerance in adults with neutropenic fever.
    Arnold HM; McKinnon PS; Augustin KM; Hladnik LM; Casabar E; Reichley RM; Dubberke ER; Westervelt P; Ritchie DJ
    Pharmacotherapy; 2009 Aug; 29(8):914-23. PubMed ID: 19637944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies.
    Lamoth F; Buclin T; Csajka C; Pascual A; Calandra T; Marchetti O
    Antimicrob Agents Chemother; 2009 Feb; 53(2):785-7. PubMed ID: 19047655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of imipenem as empirical treatment of febrile neutropenia.
    Klastersky JA
    Int J Antimicrob Agents; 2003 May; 21(5):393-402. PubMed ID: 12727070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.